1
|
D'Angelo E, Espinosa I, Ali R, Gilks CB,
Rijn Mv, Lee CH and Prat J: Uterine leiomyosarcomas: Tumor size,
mitotic index and biomarkers Ki67 and Bcl-2 identify two groups
with different prognosis. Gynecol Oncol. 121:328–333. 2011.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Italiano A, Mathoulin-Pelissier S, Cesne
AL, Terrier P, Bonvalot S, Collin F, Michels JJ, Blay JY, Coindre
JM and Bui B: Trends in survival for patients with metastatic
soft-tissue sarcoma. Cancer. 117:1049–1054. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Penel N, Van Glabbeke M, Marreaud S, Ouali
M, Blay JY and Hohenberger P: Testing new regimens in patients with
advanced soft tissue sarcoma: Analysis of publications from the
last 10 years. Ann Oncol. 22:1266–1272. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lin G, Yang LY, Huang YT, Ng KK, Ng SH,
Ueng SH, Chao A, Yen TC, Chang TC and Lai CH: Comparison of the
diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted
MRI in the differentiation between uterine leiomyosarcoma/smooth
muscle tumor with uncertain malignant potential and benign
leiomyoma. J Magn Reson Imaging. 43:333–342. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Giuntoli RL II, Metzinger DS, DiMarco CS,
Cha SS, Sloan JA, Keeney G and Gostout BS: Retrospective review of
208 patients with leiomyosarcoma of the uterus: Prognostic
indicators, surgical management and adjuvant therapy. Gynecol
Oncol. 89:460–469. 2003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Gupta AA, Yao X, Verma S, Mackay H and
Hopkins L: Sarcoma Disease Site Group and the Gynecology Cancer
Disease Site Group: Systematic chemotherapy for inoperable, locally
advanced, recurrent, or metastatic uterine leiomyosarcoma: A
systematic review. Clin Oncol (R Coll Radiol). 25:346–355. 2013.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Gupta AA, Yao X, Verma S, Mackay H and
Hopkins L: Chemotherapy (gemcitabine, docetaxel plus gemcitabine,
doxorubicin, or trabectedin) in inoperable, locally advanced,
recurrent, or metastatic uterine leiomyosarcoma: A clinical
practice guideline. Curr Oncol. 20:e448–e454. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Monk BJ, Blessing JA, Street DG, Muller
CY, Burke JJ and Hensley ML: A phase II evaluation of trabectedin
in the treatment of advanced, persistent, or recurrent uterine
leiomyosarcoma: A gynecologic oncology group study. Gynecol Oncol.
124:48–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Pautier P, Floquet A, Chevreau C, Penel N,
Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N,
Piperno-Neumann S, et al: Trabectedin in combination with
doxorubicin for first-line treatment of advanced uterine or
soft-tissue leiomyosarcoma (LMS-02): A non-randomised, multicentre,
phase 2 trial. Lancet Oncol. 16:457–464. 2015. View Article : Google Scholar : PubMed/NCBI
|